SLC5A2 and chronic kidney disease: The dynamic nature of healthcare, with potential future changes in reimbursement rates, advancements in clinical methods, and evolving treatment strategies such as the emergence of SGLT2 inhibitors as new, effective drugs for CKD management, underscores the need for flexible and forward-thinking screening strategies.